Ablynx NV

Ablynx NV is a biotechnology company that was founded in 2001 as a spin-off of the Vlaams Instituut voor Biotechnologie (VIB) and the Free University of Brussels (VUB). The company is based in Ghent, Belgium, and has about 450 employees. Since then, it has grown to become a leader in nanobody technology, with more than 500 pending and granted patents and a pipeline of over 45 programs in different stages of development.

Ablynx's main focus is on the discovery and development of nanobodies, which are proprietary therapeutic proteins based on single-domain antibody fragments. Nanobodies are derived from the heavy-chain-only antibodies found in llamas and other camelids and are about a tenth the size of conventional antibodies. This makes them more stable, versatile, and easy to produce than conventional antibodies .

Ablynx NV is also collaborating with several pharmaceutical companies, such as Sanofi, Merck & Co., Boehringer Ingelheim, and Novartis, to develop nanobody products for various indications, such as immuno-oncology, inflammation, hematology, and neuroscience.

Ablynx's vision is to become a leading biopharmaceutical company that leverages nanobody technology to create innovative and life-changing medicines for patients. The company's mission is to deliver on the promise of nanobodies by applying its scientific expertise, creativity, and passion to address unmet medical needs. Ablynx's values are excellence, innovation, teamwork, respect, and integrity.

Foundation: 2001
Headquarters: Ghent, Belgium
Website: http://www.ablynx.com